Status:
UNKNOWN
Addressing Depression and Anxiety Symptoms in Patients With Inflammatory Bowel Disease
Lead Sponsor:
Mount Sinai Hospital, Canada
Conditions:
Inflammatory Bowel Diseases
Crohn Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Inflammatory Bowel Diseases (IBD) are chronic debilitating disorders of the gastrointestinal tract that comprise two subtypes; Crohn's Disease (CD) and Ulcerative Colitis (UC). Canada has among the hi...
Detailed Description
Inflammatory Bowel Diseases (IBD) are chronic debilitating disorders of the gastrointestinal tract that comprise two subtypes; Crohn's Disease (CD) and Ulcerative Colitis (UC). Canada has among the hi...
Eligibility Criteria
Inclusion
- PHQ-9 AND/OR GAD-7 score ≥ 10
- Confirmed diagnosis of IBD (based on record of diagnostic endoscopy)
- Access to Computer or Smartphone
- Access to an Internet Connection
Exclusion
- Patients without a record of diagnostic endoscopy in their clinical record
- Under psychological treatment parallel to the intervention being carried out
- Diagnosis of major depressive, dysthymic, bipolar or psychotic disorder
- History of anti-depressant medication use within 1 month of enrollment
- History of substance abuse or dependence within 1 month of enrollment
- Previous course of CBT within 12 months of Enrollment
- History of suicide
- History of psychiatric hospitalization
- Inability to provide informed consent
- Insufficient command of written and spoken English
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03327038
Start Date
January 1 2018
End Date
January 1 2020
Last Update
April 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5